FDA Grants Orphan Drug Status To Eisai's Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma

WOODCLIFF LAKE, N.J., Aug. 8, 2013 -- (Healthcare Sales &Marketing Network) -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational compound (E7777) for cutaneous t-cell ly... Biopharmaceuticals, Oncology, FDAEisai, orphan drug, E7777, cutaneous t-cell lymphoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

This article is protected by copyright. All rights reserved. PMID: 30328116 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
PRINCETON, N.J., Oct. 15, 2018 -- (Healthcare Sales &Marketing Network) -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where t... Biopharmaceuticals, Oncology Soligenix, hypericin, cutaneous T-cell lymphoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
ConclusionBexarotene monotherapy is well-tolerated and has encouraging activity in PTCL that warrants further investigation. This agent should be considered for further prospective trials in this setting.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Photochem. Photobiol. Sci., 2018, Accepted Manuscript DOI: 10.1039/C8PP00170G, PerspectiveFranz Trautinger Cutaneous T-cell lymphomas (CTCL) are a heterogenous group of non-Hodgkin lymphomas arising in the skin. Mycosis fungoides (MF), the most common variant, is characterised by clonal proliferation of skin residing... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Photochem. Photobiol. Sci. latest articles - Category: Chemistry Authors: Source Type: research
We present a practical review of the etiology, diagnosis, and treatment of this entity. PMID: 30316452 [PubMed - as supplied by publisher]
Source: Actas Dermo-Sifiliograficas - Category: Dermatology Authors: Tags: Actas Dermosifiliogr Source Type: research
This article is protected by copyright. All rights reserved. PMID: 30298903 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
Martine Bagot, MD, PhD, of Saint Louis Hospital, Paris, France, discusses the exciting new approval of the antibody mogumulizumab for cutaneous T-cell lymphoma. Speaking at the European Organisation f... Author: VJHemOnc Added: 10/02/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Martine Bagot, MD, PhD, of Saint Louis Hospital, Paris, France, speaks at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress,... Author: VJHemOnc Added: 10/02/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Maintenance therapy options for cutaneous T-cell lymphomas could be improved. Here, Rudolf Stadler, MD, PhD, of the University Medical Center Minden, Minden, Germany, discusses the RESMAIN study (NCT0... Author: VJHemOnc Added: 10/02/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
An accurate and optimized clinical scoring system is essential for the staging and management of cutaneous T-cell lymphoma. Here, Pietro Quaglino, MD, of the University of Turin, Turin, Italy, discuss... Author: VJHemOnc Added: 10/02/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer & Oncology | Cutaneous T cell lymphoma | Food and Drug Administration (FDA) | Grants | Lymphoma | Marketing | Pharmaceuticals | T-cell Lymphoma